 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12...56789101112131415...1920» |
- Rybelsus (semaglutide oral) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Higher Adherence and Persistence for Dulaglutide Compared with Oral Semaglutide at Six-Months Follow-Up with U.S. Real-World Data (Poster Hall (Halls D-E); Board No. 92) - May 11, 2022 - Abstract #ADA2022ADA_2109;
More DU patients were persistent on therapy compared to OS patients (72% vs. 57% p<0.001) and had longer mean duration of persistence (148 vs. 128, p<0.001). Among patients with ≥2 fills of their index drug, 73% of DU and 62% of OS patients were adherent.During the 6-mo follow-up period, DU patients had significantly higher adherence and persistence compared to OS patients.
- Rybelsus (semaglutide oral) / Novo Nordisk
Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Oral Semaglutide (Poster Hall (Halls D-E); Board No. 127) - May 11, 2022 - Abstract #ADA2022ADA_1900;
Results suggest that oral sema is an effective T2DM treatment in the real-world, especially among patients with A1c values ≥9% prior to treatment initiation. Patients with T2DM in this population are more often prescribed oral sema by primary care physicians than endocrinologists.
- Rybelsus (semaglutide oral) / Novo Nordisk
Insulin-Sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8 (Poster Hall (Halls D-E); Board No. 721) - May 11, 2022 - Abstract #ADA2022ADA_1844;
P3
Greater proportions of pts on oral semaglutide 3, 7, and 14 mg achieved ≥20% reductions in insulin vs. those in the pbo group at both weeks 26 and 52 (Treatment policy estimand; 27.5%, 28.9%, 31.2% vs. 12.4% and 19.5%, 25.0%, 32.0% vs 5.7%, respectively; P<0.001 for all). Addition of oral semaglutide in pts with T2D permits a significant reduction in insulin dose, which may provide benefits (e.g. lower risk of hypoglycemia and weight gain) long-term.
- Rybelsus (semaglutide oral) / Novo Nordisk
Effects of Semaglutide Treatment on Dietary Behavior in Japanese Patients with Type 2 Diabetes Mellitus (Poster Hall (Halls D-E); Board No. 624) - May 11, 2022 - Abstract #ADA2022ADA_1412;
Objective and Eating behavior questionnaire issued by the Japan Society for the Study of Obesity was administered to 41 patients who received semaglutide injection (SI) and 52 patients who received oral semaglutide (OS) in our outpatient clinic... These results suggest that semaglutide improves glycemic control and eating behavior in Japanese patients with type 2 diabetes.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Oral Semaglutide: Dosage in Special Situations. (Pubmed Central) - May 10, 2022
Its insights assist in pragmatic placement of this drug in clinical practice. Special emphasis is laid on the use of oral semaglutide in persons already on injectable GLP-1RA formulations, those experiencing sudden changes in life style pattern due to religious, social, or professional commitments, individuals seeking help for urgent glycemic control, and those who face sudden change in their concomitant medications or comorbidities.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: https://t.co/DnxzmGRRri Some special considerations regarding scientific use of a special drug, oral semaglutide @MyWegovy @semaglutide @GLP1RA @novonordisk @ABCDiab @DiabetesHealth_ @GlucoseDoc @diabetespc @novoindia (Twitter) - May 10, 2022
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, Journal: Oral semaglutide in the management of type 2 DM: Clinical status and comparative analysis. (Pubmed Central) - May 6, 2022
Special emphasis is laid on the use of oral semaglutide in persons already on injectable GLP-1RA formulations, those experiencing sudden changes in life style pattern due to religious, social, or professional commitments, individuals seeking help for urgent glycemic control, and those who face sudden change in their concomitant medications or comorbidities. The review highlights the comparative analysis of semaglutide with the existing second-line drugs for the management of type 2 diabetes mellitus by stressing on its benefits and adverse events.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Retrospective data, Journal: Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. (Pubmed Central) - May 6, 2022
P3
These findings indicate that the CV outcomes for semaglutide were similar regardless of baseline metformin use, which may also apply to all GLP-1RAs. Trial registration SUSTAIN 6 (NCT01720446), PIONEER 6 (NCT02692716).
- Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk, Byetta (exenatide) / AstraZeneca
EFFICACY OF GLP-1 ANALOGS AND AGONISTS ON PROPORTION OF WEIGHT LOSS IN OVERWEIGHT OR OBESE DIABETICS AND NON-DIABETICS: A SYSTEMATIC REVIEW AND META-ANALYSIS (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_4650;
Trial registration SUSTAIN 6 (NCT01720446), PIONEER 6 (NCT02692716). Treatment groups were classified as: exenatide IR (immediate release), liraglutide ≤0.8mg, liraglutide >1.8mg, semaglutide subcutaneous (SQ) 5% or >10% weight loss in DM and non-DM overweight or obesity.
- | Rybelsus (semaglutide oral) / Novo Nordisk
New trial: GAROS: Genetics of the Acute Response to Oral Semaglutide (clinicaltrials.gov) - Apr 21, 2022
P=N/A, N=1000, Not yet recruiting, Sponsor: Medical University of Bialystok
- || Rybelsus (semaglutide oral) / Novo Nordisk
Attention #Pharmacists and #pharmacy students! Can you answer the NAPLEX question of the week about Rybelsus? Thanks @blandman19 and @mheducation for sharing! https://t.co/ooMwsTl5kg (Twitter) - Apr 18, 2022
- | Rybelsus (semaglutide oral) / Novo Nordisk
@novonordisk STOP MAKING YOUR RYBELSUS COMMERCIAL SO DAMN LOUD!! ITS 3X THE REGULAR VOLUME! (Twitter) - Apr 15, 2022
- | Rybelsus (semaglutide oral) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal: Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus. (Pubmed Central) - Apr 13, 2022
Therefore, the corresponding costs needed to treat are $676,385 ($498,894-$1,101,039) and $1,005,855 (95% CI $684,837-$6,270,544) respectively. In conclusion, our findings suggest that empagliflozin provides better value for money than oral semaglutide to prevent CVM in patients with type 2 diabetes mellitus at the current United States prices of the interventions.
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P4 trial: The POST-ACS Study (clinicaltrials.gov) - Apr 10, 2022
P4, N=140, Not yet recruiting, Sponsor: Swansea Bay University Health Board
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery. (Pubmed Central) - Apr 8, 2022
Not only is this a potentially life changing medicine for diabetic patients, it holds tremendous commercial potential for Novo Nordisk, with some analysts predicting the product to reach $5 billion in peak revenues [3]. In this "Inspirational Note," we summarize some of the public domain work that led to the achievement of this significant milestone and provide commentary on its potential future impact.
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: NN9924-4645: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice (clinicaltrials.gov) - Apr 6, 2022
P=N/A, N=194, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || Rybelsus (semaglutide oral) / Novo Nordisk
In India you can find its subsitute named Rybelsus manufactured by Novo Nordisk in tablet form. (Twitter) - Apr 6, 2022
- | Rybelsus (semaglutide oral) / Novo Nordisk
.@novonordisk's new #Rybelsus ad encourages doctors to make the switch with a subtle dig at competitors. #novonordisk #pharma https://t.co/zh7Pc4GFYz (Twitter) - Apr 4, 2022
- || Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Journal: Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials. (Pubmed Central) - Apr 1, 2022
In PIONEER 9 and 10, patients were randomized to once-daily oral semaglutide (3, 7 or 14 mg) or a comparator (placebo or once-daily subcutaneous liraglutide 0.9 mg [PIONEER 9]; once-weekly subcutaneous dulaglutide 0.75 mg [PIONEER 10]) for 52 weeks, with 5 weeks' follow-up...There was generally a higher rate of premature trial product discontinuation due to AEs in the older age group. These results indicate that oral semaglutide is efficacious in Japanese patients irrespective of age.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, PK/PD data, Journal: Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. (Pubmed Central) - Apr 1, 2022
P1
These results indicate that oral semaglutide is efficacious in Japanese patients irrespective of age. There was no significant difference in exposure to oral semaglutide in subjects with or without upper GI disease, hence no dose adjustment is required.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Review, Journal: Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India. (Pubmed Central) - Apr 1, 2022
Oral semaglutide 14 mg is an effective agent in the treatment of T2DM. Real-world studies of semaglutide are clearly needed in India in absence of meaningful data from RCTs in Indians.
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: OASIS 2: Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity (clinicaltrials.gov) - Apr 1, 2022
P3, N=198, Active, not recruiting, Sponsor: Novo Nordisk A/S
Real-world studies of semaglutide are clearly needed in India in absence of meaningful data from RCTs in Indians. Recruiting --> Active, not recruiting
- || Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: Wegovy (semaglutide): a new weight loss drug for chronic weight management. (Pubmed Central) - Mar 29, 2022
Trial data and other pertinent articles were obtained via database search through the US National Library of Medicine Clinical Trials and the National Center for Biotechnology Information. All three clinical trials demonstrated that semaglutide (injected or oral) has superior efficacy compared with placebo and other antidiabetic medications in weight reduction, which led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss.
- || Rybelsus (semaglutide oral) / Novo Nordisk
#Rybelsus @novonordisk (Twitter) - Mar 26, 2022
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Trial primary completion date: Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People (clinicaltrials.gov) - Mar 24, 2022
P1, N=290, Completed, Sponsor: Novo Nordisk A/S
All three clinical trials demonstrated that semaglutide (injected or oral) has superior efficacy compared with placebo and other antidiabetic medications in weight reduction, which led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss. Active, not recruiting --> Completed | Trial primary completion date: Oct 2021 --> Feb 2022
- | Rybelsus (semaglutide oral) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal, HEOR: The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark. (Pubmed Central) - Mar 23, 2022
Duration of treatment with oral semaglutide is the key driver of the analyses. Oral semaglutide+metformin seems not cost-effective versus empagliflozin+metformin in patients uncontrolled on metformin in Denmark.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Once-Weekly Semaglutide 1 mg vs Empagliflozin 25 mg as Add-On to Metformin Monotherapy in Patients with Type 2 Diabetes: a Meta-Regression Analysis of Individual Patient Data (Poster area 2) - Mar 22, 2022 - Abstract #DDG2022DDG_310;
A significantly greater proportion of patients on semaglutide vs. empagliflozin also achieved HbA1C targets and clinically relevant weight-loss targets. In this indirect comparison, pooled semaglutide 1mg provided significantly greater HbA1C reduction and body weight-loss compared with empagliflozin 25mg in patients with T2D on metformin monotherapy.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People (clinicaltrials.gov) - Mar 20, 2022
P1, N=404, Active, not recruiting, Sponsor: Novo Nordisk A/S
In this indirect comparison, pooled semaglutide 1mg provided significantly greater HbA1C reduction and body weight-loss compared with empagliflozin 25mg in patients with T2D on metformin monotherapy. Not yet recruiting --> Active, not recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk, OWL833 / Eli Lilly, danuglipron (PF-06882961) / Pfizer
Journal: Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists. (Pubmed Central) - Mar 15, 2022
Small molecule oral GLP-1 receptor agonists are currently in development, and we introduce how these chemicals have addressed the challenge posed by interactions with the large extracellular ligand binding domain of the GLP-1 receptor. We specifically discuss the structure and pharmacological properties of TT-OAD2, LY3502970, and PF-06882961, and envision an era where more patients could benefit from oral GLP-1 receptor agonist therapy.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (clinicaltrials.gov) - Mar 10, 2022
P=N/A, N=194, Active, not recruiting, Sponsor: Novo Nordisk A/S
We specifically discuss the structure and pharmacological properties of TT-OAD2, LY3502970, and PF-06882961, and envision an era where more patients could benefit from oral GLP-1 receptor agonist therapy. Enrolling by invitation --> Active, not recruiting
- || Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed, Trial completion date, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (clinicaltrials.gov) - Mar 10, 2022
P=N/A, N=194, Active, not recruiting, Sponsor: Novo Nordisk A/S
Enrolling by invitation --> Active, not recruiting Enrolling by invitation --> Active, not recruiting | Trial completion date: Jul 2022 --> Dec 2022
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS). (Pubmed Central) - Mar 9, 2022
P=N/A
This is the first study to investigate the direct and indirect anti-atherosclerotic mechanisms of oral semaglutide. The results are expected to confirm the position of oral semaglutide in the multifactorial management of T2D with an emphasis on cardiovascular disease prevention.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Cost-Effectiveness Analysis of Once-Weekly Semaglutide for the Treatment of Patients with Type 2 Diabetes in Mexico (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1691;
The results are expected to confirm the position of oral semaglutide in the multifactorial management of T2D with an emphasis on cardiovascular disease prevention. Oral Semaglutide is considered a dominant treatment option compared with GLP-1 RA, SGLT-2 and DPP-4i in the treatment of patients with type 2 diabetes in Mexico.
- Rybelsus (semaglutide oral) / Novo Nordisk
Clinical Experiences of Type 2 Diabetes (T2DM) Patients Initiating Oral Semaglutide (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_281;
After launch, the population initiating oral semaglutide experienced changes in demographic, clinical characteristics, and baseline treatment experience. It is important to understand and monitor the evolving characteristics of these patients, ensuring they have access to the appropriate medications they require at the time they need it most.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus tablets), an oral GLP-1 receptor agonist (Pubmed Central) - Mar 3, 2022
Rybelsus have been shown to be of continuous benefit in patients with type 2 diabetes at various stages by monotherapy and combination therapy with 3, 7 and 14 mg Rybelsus in eight global clinical trials and two Japanese trials. It was suggested that oral semaglutide make patients with chronic and progressive type 2 diabetes may be able to achieve the earlier improvement in glycemic control as global diabetes association recommended.
- || Rybelsus (semaglutide oral) / Novo Nordisk
When the Rybelsus hits @novonordiskus (Twitter) - Mar 3, 2022
- || Rybelsus (semaglutide oral) / Novo Nordisk
sangre. @novonordisk #diabetes #Rybelsus #obesidad #dislipidemia #higadograso #hipertension #Semaglutida #insuficienciarenal #sindromemetabolico #revolucionendiabetes #insuficienciarenalcronica (Twitter) - Mar 2, 2022
- || Rybelsus (semaglutide oral) / Novo Nordisk
Diabetes Mellitus Tipo 2. @novonordisk #diabetes #Rybelsus #Semaglutida (Twitter) - Feb 26, 2022
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, Journal: Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations. (Pubmed Central) - Feb 22, 2022
It was suggested that oral semaglutide make patients with chronic and progressive type 2 diabetes may be able to achieve the earlier improvement in glycemic control as global diabetes association recommended. No abstract available
- || Rybelsus (semaglutide oral) / Novo Nordisk
Biomarker, Clinical, Review, Journal: Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients. (Pubmed Central) - Feb 22, 2022
Oral semaglutide showed cardiovascular safety profile, with significant reduced risk of death from cardiovascular events. Based on current data, clinicians should consider oral semaglutide for type 2 diabetes management.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Trulicity (dulaglutide) / Eli Lilly
Journal, HEOR: The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. (Pubmed Central) - Feb 16, 2022
Based on current data, clinicians should consider oral semaglutide for type 2 diabetes management. Based on a willingness-to-pay threshold of EUR 30,000 per QALY gained, oral semaglutide 14 mg was considered cost-effective versus empagliflozin 25 mg and dulaglutide 1.5 mg for the treatment of type 2 diabetes in Portugal.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity (clinicaltrials.gov) - Feb 15, 2022
P1, N=60, Recruiting, Sponsor: Novo Nordisk A/S
Based on a willingness-to-pay threshold of EUR 30,000 per QALY gained, oral semaglutide 14 mg was considered cost-effective versus empagliflozin 25 mg and dulaglutide 1.5 mg for the treatment of type 2 diabetes in Portugal. Not yet recruiting --> Recruiting
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity (clinicaltrials.gov) - Feb 10, 2022
P1, N=60, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice (clinicaltrials.gov) - Feb 9, 2022
P=N/A, N=194, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice (clinicaltrials.gov) - Feb 9, 2022
P=N/A, N=462, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Retrospective data, Journal: GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. (Pubmed Central) - Feb 8, 2022
Not yet recruiting --> Recruiting GLP-1RA have moderate benefits on MACE, and also reduce hospitalization for heart failure and all-cause mortality; they also have robust benefits on reducing the incidence of macroalbuminuria.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People (clinicaltrials.gov) - Feb 7, 2022
P1, N=404, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, HEOR: A RESPONSE TO: "COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES". (Pubmed Central) - Feb 4, 2022
GLP-1RA have moderate benefits on MACE, and also reduce hospitalization for heart failure and all-cause mortality; they also have robust benefits on reducing the incidence of macroalbuminuria. No abstract available
- || Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Clinical, Journal, HEOR: Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics. (Pubmed Central) - Jan 29, 2022
Oral semaglutide is predicted to offer health benefits similar to subcutaneous semaglutide and ahead of dulaglutide and liraglutide. Oral semaglutide is a cost-effective glucagon-like peptide 1 receptor agonist treatment option.
- Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Bile acid physiology-guided oral delivery of plasmid DNA nanoparticle encoding GLP1 gene efficiently treat diabetes and morbid obesity (Virtual Room (Marriott Marquis San Diego Marina)) - Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_13683;
Regardless of dose, CAP-gene/PTCA significantly reduces total blood sugar exposure and intraperitoneal fat content, normalizes chronic HbA1c level, stimulates GLP1 and insulin secretion in the body, and restores GLP1 and insulin expressions of pancreatic beta cells. Since Rybelsus® is the only FDA-approved oral GLP1 agonist that needs to be taken with 7 or 14 mg daily, oral CaP-gene/PTCA may provide the first once or bi-monthly oral treatment option for diabetic patients.